Peer-influenced content. Sources you trust. No registration required. This is HCN.

The Epoch TimesModified RNA in COVID Vaccines May Contribute to Cancer Development: Review

Implications of Modified mRNA in Cancer Development: A Closer Look at Immune Suppression and mRNA Stability

Recent research reviews the modification of mRNA in COVID-19 vaccines, specifically the N1-methyl-pseudouridine (m1-psi) alteration, and its potential to suppress immune responses that could contribute to cancer development. This study explores the balance between vaccine efficacy and immune integrity, providing critical insights into the long-term implications of mRNA modifications.

Key Points:

  • The mRNA in COVID-19 vaccines has been modified to include N1-methyl-pseudouridine (m1-psi) to enhance stability and protein production but may suppress immune responses.
  • The modification allows mRNA to bypass rapid degradation by the immune system, enabling effective spike protein synthesis required for the vaccine’s function.
  • Researchers express concerns that m1-psi modification could potentially create an environment conducive to cancer development in genetically susceptible individuals.
  • Comparative studies on mice revealed that natural mRNA triggered a robust immune response and complete survival in melanoma models, whereas 100% modified mRNA correlated with a higher cancer growth and a 50% survival rate.
  • The review suggests future mRNA therapies should consider using a lower percentage of m1-psi modification to minimize immune suppression.
  • Experts emphasize that while m1-psi modifications reduce immunotoxicity, there is insufficient scientific support to conclude they directly cause cancer.
  • The ongoing debate underscores the need for more research into the long-term effects of modified mRNA on tumor biology and immune system responses.

“We are not affirming that mRNA vaccines cause cancer; but they could stimulate its development … We are more concerned with experimental and clinical data with regard to the latter.”
– Review Authors

More on Cancer Risk

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form